# AbbVie Inc. (ABBV) Source: https://www.quantisnow.com/company/ABBV Generated: 2026-11-11T11:05:13.133Z - Ticker: ABBV - Exchange: NYSE - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - IPO year: 2012 - SEC CIK: 0001551152 - Website: abbvie.com ## About AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois. ## Latest ABBV news and filings - 2026-11-08 17:45 UTC [Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications](https://www.quantisnow.com/insight/allergan-aesthetics-reports-improved-satisfaction-with-facial-appearance-following-aesthetic-6779796) - 2026-11-03 18:43 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by AbbVie Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-abbvie-inc-6769157) - 2026-11-03 13:00 UTC [Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026](https://www.quantisnow.com/insight/allergan-aesthetics-to-present-new-research-on-aesthetic-care-following-6768474) - 2026-11-02 21:05 UTC [SEC Form 8-K] [AbbVie Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/abbvie-inc-filed-sec-form-8-k-leadership-update-6767074) - 2026-11-02 14:00 UTC [Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies](https://www.quantisnow.com/insight/brise-pharmaceuticals-announces-global-license-agreement-with-abbvie-to-advance-6766441) - 2026-10-30 11:51 UTC [SEC Form 8-K] [AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/abbvie-inc-filed-sec-form-8-k-results-of-operations-and-6764589) - 2026-10-30 11:46 UTC [Earnings Date] [AbbVie Reports Third-Quarter 2026 Financial Results](https://www.quantisnow.com/insight/abbvie-reports-third-quarter-2026-financial-results-6764576) - 2026-10-29 10:00 UTC [AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial](https://www.quantisnow.com/insight/abbvie-temple-study-demonstrates-superior-tolerability-and-efficacy-of-atogepant-6762024) - 2026-10-28 12:00 UTC [The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18](https://www.quantisnow.com/insight/the-countdown-is-on-botox-cosmetic-onabotulinumtoxina-day-is-back-6760593) - 2026-10-27 12:30 UTC [Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)](https://www.quantisnow.com/insight/allergan-aesthetics-announces-2026-grant-recipients-of-the-confidence-collective-6758694) - 2026-10-27 12:00 UTC [AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma](https://www.quantisnow.com/insight/abbvie-submits-biologics-license-application-bla-for-etentamig-to-us-6758599) - 2026-10-26 12:00 UTC [Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.](https://www.quantisnow.com/insight/allergan-aesthetics-celebrates-eight-years-of-engaging-girls-in-stem-6757063) - 2026-10-26 08:47 UTC [FDA Approval for SKYRIZI issued to ABBVIE INC](https://www.quantisnow.com/insight/fda-approval-for-skyrizi-issued-to-abbvie-inc-6756771) - 2026-10-26 08:47 UTC [FDA Approval for SKYRIZI issued to ABBVIE INC](https://www.quantisnow.com/insight/fda-approval-for-skyrizi-issued-to-abbvie-inc-6756769) - 2026-10-23 21:04 UTC [SEC Form 3] [SEC Form 3 filed by AbbVie Inc.](https://www.quantisnow.com/insight/sec-form-3-filed-by-abbvie-inc-6756577) - 2026-10-23 19:33 UTC [U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease](https://www.quantisnow.com/insight/us-fda-approves-subcutaneous-induction-regimen-for-abbvies-skyrizi-risankizumab-rzaa-6756205) - 2026-10-22 13:00 UTC [AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa](https://www.quantisnow.com/insight/abbvie-announces-topline-results-from-the-phase-3-intrepid-trial-6754656) - 2026-10-21 12:00 UTC [Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence](https://www.quantisnow.com/insight/allergan-aesthetics-deepens-science-behind-multimodal-approach-at-amwc-dubai-6752993) - 2026-10-21 11:02 UTC [AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian Cancer](https://www.quantisnow.com/insight/abbvie-reaches-agreement-with-the-pan-canadian-pharmaceutical-alliance-pcpa-for-6752853) - 2026-10-20 12:01 UTC [Health Canada Approves SKYRIZI® (risankizumab) for Children Living with Moderate to Severe Plaque Psoriasis](https://www.quantisnow.com/insight/health-canada-approves-skyrizi-risankizumab-for-children-living-with-moderate-6751562) - 2026-10-19 08:00 UTC [AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease](https://www.quantisnow.com/insight/abbvie-presents-data-for-abbv-466-a-novel-dual-targeting-therapy-demonstrating-6749745) - 2026-10-18 22:09 UTC [/C O R R E C T I O N - AbbVie/](https://www.quantisnow.com/insight/c-o-r-r-e-c-t-i-o-n-6749731) - 2026-10-18 22:10 UTC [AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio](https://www.quantisnow.com/insight/abbvie-to-present-data-at-the-2026-european-society-for-6749728) - 2026-10-17 06:00 UTC [SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026](https://www.quantisnow.com/insight/skyrizi-risankizumab-and-rinvoq-upadacitinib-data-highlight-long-term-clinical-and-6749718) - 2026-10-15 20:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by AbbVie Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-abbvie-inc-6747925) - 2026-10-13 19:15 UTC [AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease](https://www.quantisnow.com/insight/abbvie-presents-new-phase-3-affirm-data-showing-clinical-and-6744871) - 2026-10-11 17:00 UTC [New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease](https://www.quantisnow.com/insight/new-skyrizi-risankizumab-rzaa-and-rinvoq-upadacitinib-data-demonstrate-disease-control-6743367) - 2026-10-07 12:30 UTC [AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC](https://www.quantisnow.com/insight/abbvies-telisotuzumab-adizutecan-temab-a-receives-two-breakthrough-therapy-designations-from-6739834) - 2026-10-05 20:07 UTC [SEC Form 8-K] [SEC Form 8-K filed by AbbVie Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-abbvie-inc-6736818) - 2026-10-02 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Rapp Edward J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-rapp-edward-j-6735102) - 2026-10-02 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Quaggin Susan E](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-quaggin-susan-e-6735098) - 2026-10-01 14:00 UTC [AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo](https://www.quantisnow.com/insight/abbvie-presents-long-term-rinvoq-upadacitinib-data-showing-continued-repigmentation-in-6731884) - 2026-10-01 12:00 UTC [Earnings Date] [AbbVie to Host Third-Quarter 2026 Earnings Conference Call](https://www.quantisnow.com/insight/abbvie-to-host-third-quarter-2026-earnings-conference-call-6731504) - 2026-09-30 12:20 UTC [FDA Approval for JUVMO issued to ABBVIE INC](https://www.quantisnow.com/insight/fda-approval-for-juvmo-issued-to-abbvie-inc-6730048) - 2026-09-30 09:45 UTC [AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026](https://www.quantisnow.com/insight/abbvie-presents-detailed-phase-1-data-for-abbv-295-a-long-acting-6729738) - 2026-09-30 05:30 UTC [AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026](https://www.quantisnow.com/insight/abbvie-highlights-positive-results-from-the-phase-2-apex-part-6729718) - 2026-09-30 05:00 UTC [AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress](https://www.quantisnow.com/insight/abbvie-showcases-leadership-in-dermatology-research-with-new-clinical-and-6729716) - 2026-09-29 13:00 UTC [AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development](https://www.quantisnow.com/insight/abbvie-partners-with-valkai-to-apply-advanced-ai-across-targeted-6728793) - 2026-09-28 12:00 UTC [U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease](https://www.quantisnow.com/insight/us-fda-approves-abbvies-juvmo-tavapadon-for-parkinsons-disease-6727169) - 2026-09-24 11:01 UTC [EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma](https://www.quantisnow.com/insight/epkinly-receives-health-canada-approval-for-adults-with-follicular-lymphoma-6724765) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ABBV - Earnings history: https://www.quantisnow.com/earnings/ABBV - Dividend history: https://www.quantisnow.com/dividends/ABBV - Insider transactions: https://www.quantisnow.com/insiders/ABBV - Options chain: https://www.quantisnow.com/options/ABBV - SEC 8-K filings only: https://www.quantisnow.com/company/ABBV/8-k - RSS and alerts for ABBV: https://www.quantisnow.com/docs/rss-feeds.md